RedHill Biopharma Seeks Patients for Phase III Crohn’s Disease Treatment Drug Trial

Israel-based RedHill Biopharma has begun a Phase III clinical study of its fixed-dose RHB-104, a drug to treat patients with moderately to severely active Crohn’s disease.

Advertisement

The biopharmaceutical company is screening patients for its randomized, double-blind, placebo-controlled U.S. study.

The drug is a proprietary combination antibiotic therapy in oral pill formulation. Researchers are looking for 240 patients in 50 clinical sites throughout the U.S., Canada and Israel.

More Articles on Gastroenterology:
Dr. Gurpreet Singh Joins Woodland Healthcare in California
7 Ways to Use Key Quality Metrics to Improve Gastroenterology Centers
Drs. Anthony Masciarelli, Renjy Vattasseril Join Cape Regional Medical Center’s ASC

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.